Intermittent short courses of cyclosporin (Neoral®) for psoriasis unresponsive to topical therapy: A 1-year multicentre, randomized study

British Journal of Dermatology

Volumn 141, Issue 2, 1999, Pages 283-291

  Ho, V C ^a   Griffiths, C E M ^b   Albrecht, G ^c   Vanaclocha, F ^d   Leon Dorantes G ^e   Atakan, N ^f   Reitamo, S ^g   Johannesson, A ^h   Mork N J ⁱ   Clarke, P ^j   Pfister, P ^k   Paul, C ^k  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Vivantes Klinikum Spandau   (Germany)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e HOSPITAL GENERAL DE MÉXICO   (Mexico)

^f HACETTEPE UNIVERSITY   (Turkey)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h Vällingby Medical Center   (Sweden)

ⁱ OSLO UNIVERSITY HOSPITAL   (Norway)

^j Hartington Statistics and Data Management Ltd   (United Kingdom)

^k NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

Cyclosporin; Intermittent courses; Psoriasis; Relapse rate; Side effects

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROEMULSION; MULTICENTER STUDY; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; CREATININE; CYCLOSPORINE; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERTENSION; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; RECURRENCE; TREATMENT OUTCOME;

EID: 0032792540     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1999.02977.x     Document Type: Article

References (25)

1. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132: 236-44.
2. Spuls PI, Witkamp L, Bossuyt PMM, Bos JD, A systematic review of five systemic treatments for severe psoriasis. Br J Dermatol 1997; 117: 943-9.
3. Stern RS, Laird N, Melski J et al. Cutaneous squamous-cell curcinoma in patients treated with PUVA. N Engl J Med 1984: 310; 1156-61.
4. Stern RS, Nichols KT, Väkevä LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psorulen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med 1997; 336; 1041-5.
5. Roenigk HH Jr, Auerhach R, Maibach H et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998; 38: 478-85.
6. Paul C, Dubertret L. Etretinate and acitretin: strategy for use and long-term side effects, In: Psoriasis (Roenigk HH Jr, Maibach HI, eds). 3rd edn. New York: Marcel Dekker, 1998: 671-83.
7. Ellis CN, Gorsulowsky DC, Hamilton TA et al. Cyclosporin Improves psoriasis in a double-blind study. JAMA 1986; 256: 3110-16.
8. Van Joost T, Bos JD, Heule F, Meinardi MMHM. Low-dose cyclosporin A in severe psoriasis. A double-blind study. Br J Dermatol 1988; 118; 183-90.
9. Ellis CN, Fradin MS, Messana JM et al. Cyclosporin for plaque-type psorinsis. Results of a multidose, double-blind trial. N Engl J Med 1991;324: 277-84.
10. Christophers E, Mrowietz U, Henneicke HH et al. Cyclosporin in psoriasis: a multicenter dose-finding study in severe plaque psoriasis. The German Multicenter Study. J Am Acad Dermatol 1992: 26: 86-90.
11. Ellis CN, Fradin MS. Hamilton TA. Voorhees JJ. Duration of remission during maintenance cyclosporin therapy for psoriasts. Relationship to maintenance dose and degree of improvement during initial therapy. Arch Dermatol 1995; 131: 791-5.
12. Shupack J, Abel K, Bauer E et al. Cydosporin as maintenance therapy in patients with severe psoriasis. J Am Acad Dermatol 1997; 36:423-32.
13. Berth-Jones J, Voorhees JJ. Consensus conference on cyclosporin A microemulsion for psoriasis, June 1996. Br J Dermatol 1996; 135; 775-7.
14. Berth-Jones J, Henderson CA, Munro CS et al. Treatment of psoriasis with intermittent short course cyclosporin (Neoral). A multicentre study. Br J Dermatol 1947; 136: 527-30.
15. Gross F, Pisa Z, Strasser T, Zanchetti A. Management of Arterial Hypertension. Geneva: World Health Organization, 1984.
16. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
17. Zachariae H, Steen Olsen T, Efficacy of cyclosporin A (CyA) in psoriasis: an overview of dose/response, indications, containdica-tions and side-effects. Clin Nephrol 1995; 43: 154-8.
18. Higgins E, Munro C, Marks J et al. Relapse rates in moderately severe chronic psoriasis treated with cyclosporin A. Br J Dermatol 1989; 121: 71-4.
19. Koo J for the OLP302 Study Group. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin. Neoral and Sandimmun, in patients with severe psoriasis, Br J Dermatol 1998; 139; 86-93.
20. Zachariae H. Long-term use of cyclosporin in dermatology. Arch Dermatol 1996; 132: 692-4.
21. Feutren G, Mihatsch MJ. Risk factors for cyclosporin-induced nephropathy in pattents with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporin in Autoimmune Diseases. N Engl J Med 1992; 326: 1654-60.
22. Powles AV, Hardman CM, Porter WM et al. Renal function after 10 years' treatment with cyclosporin for psoriasis. Br J Dermatol 1998; 138: 443-9.
23. Pei Y, Scholey JW, Katz A et al. Chronic nephrotoxicity in psoriatic patients treated with low-dose cyclosporin. Am J Kidney Dis 1994; 23: 528-36.
24. Laburte C, Grossman R, Abi-Rached J et al. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br J Dermatol 1994; 130: 366-75.
25. Grossmann RM, Chevret S, Abi-Rached J et al. Long-term safety of cyclosporin in the treatment of psoriasis. Arch Dermatol 1996; 132: 625-9.